Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.

Abstract excerpt

Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to approximately 13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. However, accumulating evidence clearly indicates that other genetic factors (e.g., major...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Age of Onset
• Share to Blood Coagulation Factor Inhibitors
• Share to Environment